The collaboration will see the two companies exploring new R&D and commercialisation in the hope of producing a preventative treatment for shingles – herpes zoster virus (HZV) – which is believed to impact around one in three people in the US during their lifetime.
According to the terms of the agreement, Pfizer will pay BioNTech $225m in upfront costs, while BioNTech will pay Pfizer $25m for the company’s proprietary antigen technology.
